Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
SC 13G/AAmendment to a previously filed SC 13GFeb 27, 2018View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2018View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderFeb 12, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 8, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 5, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GJan 26, 2018View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderNov 17, 2017View HTMLDownload DOCDownload PDF
FWPFree Writing ProspectusAug 9, 2017View HTMLDownload DOCDownload PDFDownload XLS
305B2Initial statement filed pursuant to the Trust Indenture ActAug 8, 2017View HTMLDownload DOCDownload PDFDownload XLS

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information